Identifying in vivo DCE MRI markers associated with microvessel architecture and gleason grades of prostate cancer
暂无分享,去创建一个
Anant Madabhushi | Michael Feldman | John Tomaszewski | Mirabela Rusu | Mark Rosen | Asha Singanamalli | Amy Ziober | A. Madabhushi | M. Feldman | M. Rosen | M. Rusu | A. Ziober | J. Tomaszewski | Li-ping Wang | N. Shih | Rachel E Sparks | Natalie N C Shih | Li-Ping Wang | A. Singanamalli | Rachel E. Sparks
[1] B. Trock,et al. Biopsy criteria for determining appropriateness for active surveillance in the modern era. , 2014, Urology.
[2] H. Huisman,et al. Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer , 2014, European Radiology.
[3] Andrew Janowczyk,et al. High-Throughput Biomarker Segmentation on Ovarian Cancer Tissue Microarrays via Hierarchical Normalized Cuts , 2012, IEEE Transactions on Biomedical Engineering.
[4] Anant Madabhushi,et al. Cascaded discrimination of normal, abnormal, and confounder classes in histopathology: Gleason grading of prostate cancer , 2012, BMC Bioinformatics.
[5] Anant Madabhushi,et al. Histostitcher™: An informatics software platform for reconstructing whole-mount prostate histology using the extensible imaging platform framework , 2014, Journal of pathology informatics.
[6] Edward V R Dibella,et al. The effect of temporal sampling on quantitative pharmacokinetic and three-time-point analysis of breast DCE-MRI. , 2012, Magnetic resonance imaging.
[7] Matthias Taupitz,et al. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. , 2009, Radiology.
[8] Milan Sonka,et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. , 2012, Magnetic resonance imaging.
[9] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[10] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[11] W. I. Tseng,et al. Washout gradient in dynamic contrast‐enhanced MRI is associated with tumor aggressiveness of prostate cancer , 2012, Journal of magnetic resonance imaging : JMRI.
[12] C. von Bodman,et al. Comprehensive report on prostate cancer misclassification by 16 currently used low‐risk and active surveillance criteria , 2012, BJU international.
[13] R Novario,et al. Microvessel density in prostate carcinoma , 2002, Prostate Cancer and Prostatic Diseases.
[14] Thorsten Schlomm,et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study , 2010, World Journal of Urology.
[15] Aytekin Oto,et al. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. , 2013, Human pathology.
[16] Gyan Bhanot,et al. Computerized Image-Based Detection and Grading of Lymphocytic Infiltration in HER2+ Breast Cancer Histopathology , 2010, IEEE Transactions on Biomedical Engineering.
[17] Jing Ma,et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Fred L. Bookstein,et al. Principal Warps: Thin-Plate Splines and the Decomposition of Deformations , 1989, IEEE Trans. Pattern Anal. Mach. Intell..
[19] E D Crawford,et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. , 1996, Urology.
[20] Anant Madabhushi,et al. HistoStitcher©: An interactive program for accurate and rapid reconstruction of digitized whole histological sections from tissue fragments , 2011, Comput. Medical Imaging Graph..
[21] Ulf-Dietrich Braumann,et al. Classifying prostate cancer malignancy by quantitative histomorphometry. , 2012, The Journal of urology.
[22] R. Shah,et al. Current perspectives on the Gleason grading of prostate cancer. , 2009, Archives of pathology & laboratory medicine.
[23] A. D'Amico,et al. Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.
[24] V. Master,et al. Recent Trends in Prostate Cancer Incidence by Age, Cancer Stage, and Grade, the United States, 2001–2007 , 2012, Prostate cancer.
[25] Lawrence D. True,et al. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D , 2014, Archives of pathology & laboratory medicine.
[26] Thomas Hambrock,et al. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. , 2013, European urology.
[27] Stacey A. Kenfield,et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Maté Mate. [Radical prostatectomy versus observation for localized prostate cancer]. , 2013, Revista clinica espanola.
[29] P. Johnstone,et al. Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance. , 2012, Urology.
[30] L. Salomon,et al. [CCAFU Recommendations 2013: Prostate cancer]. , 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[31] Anant Madabhushi,et al. Determining histology-MRI slice correspondences for defining MRI-based disease signatures of prostate cancer , 2011, Comput. Medical Imaging Graph..
[32] Y. Collan,et al. Prognostic factors in prostate cancer , 2006, Diagnostic pathology.
[33] Danny Vesprini,et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Cooperberg,et al. Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy , 2012, Clinical Cancer Research.
[35] J. Epstein,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.
[36] L. Klotz,et al. Cancer overdiagnosis and overtreatment , 2012, Current opinion in urology.